Morgan Stanley lowered the firm’s price target on Clorox (CLX) to $97 from $110 and keeps an Equal Weight rating on the shares. Sales struggles are persisting, particularly in litter and salad dressing, and cost pressures are ramping with limited pricing offsets, meaning consensus needs to come down, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX: